Plavix Tablet (Clopidogrel Hydrogen Sulfate)

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer 75 mg of clopidogrel orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start with a loading dose of 300 mg of this medication orally once daily on the first day of treatment, followed by a maintenance dose of 75 mg orally once daily. Aspirin 75 ～ 325 mg should be administered concomitantly with this medication once daily. 3. For patients with atrial fibrillation, administer 75 mg of this medication orally once daily. Aspirin 75 ～ 100 mg should be administered concomitantly with this medication once daily. ○ Patients with renal impairment: Experience with treatment in patients with renal impairment is limited. ○ Patients with hepatic impairment: Experience with treatment in patients with moderate hepatic disease and a bleeding diathesis is limited. This medication may be administered with or without food.

This medication prevents blood platelets from clumping together to prevent the formation of blood clots. The drug is activated in the liver by a specific enzyme, CYP2C19. Caution is needed as the effectiveness may be reduced in individuals with diminished enzyme function. Additionally, taking medications that activate this enzyme alongside this drug can enhance its effect and increase the risk of bleeding, so co-administration should be avoided. Patients with allergies to this medication or its components, those with bleeding disorders, severe liver damage, breastfeeding women, and individuals with lactose intolerance should not use it. Patients with a high risk of bleeding, reduced liver or kidney function, those who have recently experienced a stroke, hypertensive patients, and the elderly should use this medication cautiously and should consult a healthcare provider immediately if bleeding symptoms appear. This drug may increase the risk of bleeding when taken with other antiplatelet medications or drugs affecting blood coagulation, so caution is necessary when co-administered. During pregnancy, the risk to the fetus is minimal; however, caution should be exercised due to potential bleeding at delivery, and breastfeeding women should determine usage in consultation with their physician. Due to insufficient safety and efficacy data, it is not recommended for use in children. In case of overdose, the risk of bleeding may increase significantly, so the dosage must be adhered to precisely. If severe bleeding occurs, treatment such as platelet transfusion may be required. While taking this medication, bleeding may occur more easily, so patients should promptly inform their healthcare provider if they experience injuries or prolonged bleeding. When undergoing surgery or dental procedures, it is important to inform the healthcare provider that this medication is being taken, and it may be necessary to discontinue use 5-7 days prior to surgery if required. This medication should be kept out of reach of children and it is advisable not to transfer it to other containers.

• Hemorrhage
• gastrointestinal bleeding
• purpura
• contusion
• hematoma
• epistaxis
• hematoma
• hematuria
• intraocular hemorrhage
• intracranial hemorrhage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is important to maintain a storage temperature between 1 to 30 degrees Celsius to preserve its efficacy and safety for an extended period.

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle